Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study [Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3? línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o locamente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE]

Trial Profile

Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study [Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3? línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o locamente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE]

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms OnSITE
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 29 Sep 2016 According to Eisai media release, subanalyses from this study will be presented at the European Society for Medical Oncology (ESMO) Congress.
    • 11 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top